Drugs / Glutathione
Glutathione
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05371288 | Jun → Sep 2025 | COVID-19 | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07572890 | May 2026 → Jan 2028 expected | chronic kidney disease | Adia Med of Winter Park LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06896422 | Jun 2025 → Dec 2026 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 1 | NCT04105504 | Apr → Jun 2018 | hyperpigmentation of the skin | Dr Irma Bernadette S Sitohang | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02848417 | Apr 2016 → Aug 2019 | persian gulf syndrome | South Florida Veterans Affairs Foundation for Research and Education | Unknown | No outcome recorded |
| Phase 26 trials · 2 missed | ||||||
| Phase 2 | NCT07595705 | Aug 2025 → Jan 2027 expected | gingival disorder | Cairo University | Recruiting | No outcome recorded |
| Phase 2 | NCT07263841 | Jun → Dec 2025 overdue | hyperpigmentation of the skin | King Edward Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05266417 | Feb 2022 → Jan 2027 expected | Parkinson disease | Gateway Institute for Brain Research | Recruiting | No outcome recorded |
| Phase 2 | NCT03020719 | Jun 2017 → Dec 2018 | cystic fibrosis | University of Minnesota | Completed | Missed primary |
| Phase 2 | NCT00506688 | Jul 2007 → May 2010 | cystic fibrosis | Mukoviszidose Institut gGmbH | Completed | Missed primary |
| Phase 2 | NCT01177319 | Sep 2003 → Mar 2007 | Parkinson disease | University of South Florida | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT01450267 | Jun 2010 → May 2012 | cystic fibrosis | Serafino A. Marsico | Unknown | Missed primary |
| Phase 3 | NCT02311907 | Dec 2009 → Aug 2012 | chemotherapy-induced toxicity, fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma +2 | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT05954052 | Jul 2019 → Aug 2023 | autism spectrum disorder | University of Chicago | Terminated | Missed primary Stop: Business |
| Phase not applicable5 trials | ||||||
| — | NCT04816487 | May → Aug 2021 | sensorineural hearing loss, retinal pigment epithelium lesions, discolored teeth | Cairo University | Unknown | No outcome recorded |
| — | NCT01142024 | Mar 2010 → Mar 2011 | — | Huashan Hospital | Completed | No outcome recorded |
| — | NCT01044277 | Feb 2010 → Sep 2011 | — | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT00127309 | Jun → Aug 2005 | alcohol-related disorders | Piyavate Hospital | Completed | No outcome recorded |
| — | NCT00227058 | Jan → Nov 2005 | seasonal allergic rhinitis | University of Mississippi Medical Center | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 1 | NCT07622316 Background | Jun → Dec 2026 expected | autism | Greater Atlanta Integrative Pediatrics | Recruiting | No outcome recorded |
| Phase 1 | NCT07304440 Background | May 2026 → Jun 2028 expected | autism | Adia Med of Winter Park LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT01398748 Comparator | Jul 2012 → Jan 2016 | Parkinson disease | Bastyr University | Completed | No outcome recorded |
| Phase 1 | NCT01016080 Comparator | Feb → May 2009 | hyperpigmentation of the skin | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2 | NCT06620523 Comparator | Jul 2024 → Jun 2027 expected | coronary artery disorder, kidney failure | George Washington University | Recruiting | No outcome recorded |
| Phase 2 | NCT02251041 Comparator | Sep 2014 → Feb 2019 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT00323583 Background | May 2006 → ? | pancreatic adenocarcinoma | Seattle Cancer Treatment and Wellness Center | Unknown | No outcome recorded |
| Phase 3 | NCT02584283 Background | Jan 2016 → Jan 2020 | biliary tract disorder, chronic liver failure | Robert J. Porte | Completed | No outcome recorded |
| — | NCT06922669 Background | Jun 2025 → Mar 2027 expected | drug-induced liver injury | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| — | NCT00889538 Comparator | Apr 2009 → Sep 2012 | autism, disruptive behavior disorder | University of Louisville | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glutathione | “Glutathione (GSH) is widely used drug available in topical, oral and parenteral formulations with indications encompassing hyperpigmentation, anti-aging and antioxidant effects.8” NCT07263841 ↗28“Insulin (Novolin R) and Glutathione (INS-GSH)” NCT05266417 ↗ |
| Known as | GSH | “Glutathione (GSH) is widely used drug available in topical, oral and parenteral formulations with indications encompassing hyperpigmentation, anti-aging and antioxidant effects.8” NCT07263841 ↗2“daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH)” NCT06620523 ↗ “Glutathione (GSH) is a tri-peptide biomolecule” NCT04816487 ↗ |
| Known as | L-glutathione | “Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)” NCT07622316 ↗1“Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)” NCT07572890 ↗ |
| Known as | L-Glutathione Reduced | “receive either L-Glutathione Reduced (GSH) or placebo given orally (tid) for 24 weeks” NCT03020719 ↗ |
| Known as | Reduced Glutathione | “Inhaled Reduced Glutathione” NCT01450267 ↗ |
| Action | Inhibit | “It improves skin pigmentation by shifting melanogenesis from eumelanin (black brown in color) to pheomelanin (yellow red in color) through inhibiting tyrosinase enzyme, thus...” NCT07263841 ↗ |
| Modality | Peptide | “Glutathione (a tripeptide of 3 amino acids - glutamic acid, cysteine and glycine)” NCT00127309 ↗ |
| Route | Inhaled | “inhaled glutathione” NCT00506688 ↗ |